文献速递消化系统肿瘤

结直肠癌肝转移切除术后辅助FOLFOX/FOLFIRI联合或不联合氟尿苷肝动脉灌注的安全性与疗效(HARVEST试验):一项随机对照试验

Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.
PubMed 文献 · Eur J Cancer · 2024-11-30

HARVEST是一项开放标签随机对照试验,2018年5月至2021年8月入组可切除原发灶和结直肠癌肝转移患者,随机接受单纯全身化疗或联合氟尿苷肝动脉灌注,因氟尿苷生产短缺在入组92例后提前终止。改良意向治疗分析77例,3年无复发生存率两组无显著差异(31.4% vs 34.4%,P=0.28),但肝动脉灌注组1年无复发生存改善且预期5年总生存更长,除ALT升高更常见外化疗相关不良事件相当。

要点

  • 3年无复发生存率肝动脉灌注组31.4% vs 非肝动脉灌注组34.4%,P=0.28,无显著差异。
  • 肝动脉灌注组1年无复发生存改善,预期5年总生存更长。
  • 除ALT升高更常见外,两组化疗相关不良事件相当。

核心结论

  • 研究显示3年无复发生存率无显著差异,但辅助化疗联合氟尿苷肝动脉灌注可行,可能带来早期无复发生存获益和长期总生存获益。
  • 需要更大样本量进行验证并识别可能从该方案获益的患者亚组。

研究设计与样本

  • HARVEST试验为开放标签随机对照研究,2018年5月至2021年8月开展。
  • 入组可切除原发肿瘤和结直肠癌肝转移的结直肠癌患者,随机接受单纯标准全身化疗(非肝动脉灌注组)或联合氟尿苷肝动脉灌注(肝动脉灌注组)。
  • 因氟尿苷生产短缺,研究在入组92例患者后提前终止。
  • 主要终点为3年无复发生存率,次要终点包括总生存、肝脏特异性无复发生存和不良事件。
  • 92例随机患者中77例纳入改良意向治疗分析。

主要发现

  • 肝动脉灌注组(N=38)与非肝动脉灌注组(N=39)的3年无复发生存率分别为31.4%和34.4%,P=0.28。
  • 肝动脉灌注组观察到1年无复发生存改善和预期5年总生存更长。
  • 探索性亚组分析提示多发肝转移、RAS/BRAF突变和术后ctDNA甲基化阳性的患者可能有无复发生存获益,但多变量分析未将这些确定为独立因素。
  • 安全性分析显示化疗相关不良事件相当,但肝动脉灌注组ALT升高发生率更高。

局限性

  • 因氟尿苷生产短缺,研究在入组92例患者后提前终止。
  • 需要更大样本量进行验证并识别可能从该方案获益的患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatic artery infusion (HAI) chemotherapy, particularly with floxuridine (FUDR), has previously shown effectiveness in improving recurrence-free survival (RFS) in colorectal cancer (CRC) patients with colorectal liver metastases (CRLM). Nonetheless, its adjuvant use alongside modern systemic chemotherapy remains unevaluated. PATIENTS AND METHODS: The HARVEST trial is an open-label, randomized, controlled study conducted from May 2018 to August 2021. CRC patients with resectable primary tumors and CRLM were recruited and randomized to receive standard systemic chemotherapy only (non-HAI group) or in combination with HAI-FUDR (HAI group). However, due to a FUDR manufacturing shortage, the study was terminated early after enrolling 92 patients. The primary endpoint was the 3-year RFS rate, with secondary endpoints including overall survival (OS), liver-specific RFS, and adverse events. RESULTS: Of the 92 randomized patients, 77 were included in the modified intention-to-treat analysis. Three-year RFS rates were comparable between the HAI (N = 38) and non-HAI (N = 39) groups (31.4 % vs. 34.4 %; P = 0.28). However, improved 1-year RFS and a longer expected five-year OS were observed in the HAI group. While exploratory subgroup analysis suggested potential RFS benefits for patients with multiple liver metastases, RAS/BRAF mutations, and positive postoperative ctDNA methylation, multivariable analysis did not identify these as independent factors. Safety analysis showed comparable chemotherapy-related adverse events, except for a higher occurrence of ALT elevation in the HAI group. CONCLUSIONS: While our study showed no significant difference in three-year RFS, adjuvant chemotherapy intensification with HAI-FUDR is feasible and may offer early benefits in RFS and long-term OS. Nonetheless, a larger sample size is needed for validation and identifying which patient subgroup might benefit from this regimen. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03500874.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wang DS, Pat Fong W, Wen L, et al. Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial. Eur J Cancer. 2024. PMID: 39644535. doi:10.1016/j.ejca.2024.115154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。